Financials Biophytis S.A. Euronext Paris
Equities
ALBPS
FR0012816825
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.85 EUR | 0.00% | +1.19% | -58.33% |
May. 14 | Biophytis unveils design for obesity study | CF |
May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 91.84 | 62.22 | 7.534 | 3.635 | 1.945 | - | - |
Enterprise Value (EV) 1 | 91.84 | 62.22 | 7.534 | 3.635 | 1.945 | 1.945 | 1.945 |
P/E ratio | -3.29 x | -1.9 x | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 0.41 x | 0.1 x |
EV / Revenue | - | - | - | - | - | 0.41 x | 0.1 x |
EV / EBITDA | - | - | -0.33 x | - | -0.13 x | -0.14 x | -0.36 x |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 249 | 314 | 409 | 1,782 | 2,861 | - | - |
Reference price 2 | 368.4 | 198.0 | 18.40 | 2.040 | 0.6800 | 0.6800 | 0.6800 |
Announcement Date | 3/12/21 | 4/7/22 | 4/19/23 | 4/8/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 4.8 | 18.7 |
EBITDA 1 | - | - | -22.79 | - | -14.8 | -13.9 | -5.4 |
EBIT 1 | - | -26.82 | -23.27 | -14.33 | -14.8 | -13.9 | -5.4 |
Operating Margin | - | - | - | - | - | -289.58% | -28.88% |
Earnings before Tax (EBT) 1 | - | -31.25 | -24.22 | -17.03 | -19.8 | -16.9 | -8.4 |
Net income 1 | -17.05 | -31.25 | -24.22 | -17.03 | -19.8 | -16.9 | -8.4 |
Net margin | - | - | - | - | - | -352.08% | -44.92% |
EPS | -112.0 | -104.0 | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/12/21 | 4/7/22 | 4/19/23 | 4/8/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | -11.77 | -11.02 | -6.268 | - | -6.5 | -8.3 |
EBIT | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -18 | -12.4 | -11.82 | -7.764 | - | -7.8 | -12.1 |
Net income 1 | -15.86 | -18 | -12.4 | -11.82 | -7.764 | - | -7.8 | -12.1 |
Net margin | - | - | - | - | - | - | - | - |
EPS | -56.00 | -56.00 | -32.00 | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 9/17/21 | 4/7/22 | 1/31/23 | 4/19/23 | 9/27/23 | 4/8/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/12/21 | 4/7/22 | 4/19/23 | 4/8/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock
- Financials Biophytis S.A.